

Oral Glycopyrrolate Therapeutic Cheat Sheet

COMPILED BY: AZAM QURESHI, MD • REVIEWED BY: ADAM FRIEDMAN, MD

TRADE NAME

- > Glycate®
- > Robinul® and Robinul® Forte
- > Cuvposa®

MECHANISM OF ACTION

- > Competitive inhibitor of acetylcholine at M3 muscarinic receptor on post-synaptic neurons, thereby inhibiting sympathetic stimulation of eccrine sweat gland and sweat production³

FDA APPROVED FOR

- > Chronic drooling (Cuvposa®)⁴

OFF-LABEL USES

- > Primary focal hyperhidrosis¹⁻³
 - > Axillary hyperhidrosis
 - > Facial hyperhidrosis
- > Pediatric and adolescent hyperhidrosis
- > Hailey-Hailey disease⁹

DOSING

- > Children up until age 19: variable dosing regimens have been utilized, weight-based dose of 0.05-0.06 mg/kg/day in 1 or 2 divided doses supported by recent literature⁴
- > Adults: variable dosing regimens have been utilized, 1 to 2 mg once or twice daily, titrating upwards weekly based on treatment response and tolerability supported by literature^{1,2,4}
 - > Maximum of 8 mg per day^{2,7,8}

WARNINGS

- > Patients should proceed cautiously if they have history of cardiovascular disease, gastroesophageal reflux, bladder obstructions, or glaucoma⁹⁻¹²
- > Neonates: Dosage forms may contain propylene glycol, which has previously been shown to be associated with metabolic acidosis, seizures, renal failure, and central nervous system depression with excessive systemic administration (>3,000 mg/day)⁹⁻¹⁰

SIDE EFFECTS 9-10

- > Most commonly (occurring in 15% or more patients): vomiting, dry mouth, constipation, flushing, nasal congestion, sinusitis, upper respiratory tract infection, headache, urinary retention
- > Other side effects that may be less common:
 - > Mydriasis, increased intraocular pressure
 - > Arrhythmias
 - > Hypohidrosis
 - > Impotence
 - > Urinary hesitancy
 - > Decreased gastric motility and secretion, pseudo-obstruction
 - > Compensatory hyperhidrosis¹¹

CONTRAINDICATIONS 9-10

- > Hypersensitivity to glycopyrrolate
- > History of myasthenia gravis
- > History of severe ulcerative colitis, toxic megacolon, paralytic ileus, obstructive disease of GI tract, intestinal atony, obstructive uropathy
- > Unstable cardiovascular status
- > Glaucoma

PREGNANCY & BREASTFEEDING 9-10

- > No adequate and well-controlled studies of the effects of oral glycopyrrolate on pregnant humans, further study is needed
- > Given glycopyrrolate serves as an anti-cholinergic medication, it may suppress lactation
- > It is not known if glycopyrrolate is present in breast milk

MONITORING 9-10

- > Monitor for heart rate, bowel sounds & movements
- > No recommended lab monitoring